Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesGood Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part V
Value in Health, 10/29/09
Mycka JM et al. – Understanding and accounting for all costs and consequences of the use of a medical treatment is in the best interests of all parties involved in the prescribing, consuming, reimbursement, selling, and manufacturing of bio/pharmaceuticals. Transparency, consistency, and clear communication of costs and value are essential for appropriate decision–making and should be important goals for all parties.
Related Articles
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations
Value in Health, 11/11/09
Relevance Score: 71%
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part III
Value in Health, 10/29/09
Relevance Score: 71%
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09
Relevance Score: 71%
Value-Based Insurance Design in Medicare
Applied Health Economics and Health Policy, 10/20/09
Relevance Score: 70%
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09
Relevance Score: 69%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics
Journal of Clinical Pharmacy and Therapeutics, 03/19/10
Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis
PharmacoEconomics, 03/16/10
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
European Journal of Clinical Pharmacology, 03/16/10
Article Search
Sponsor
Sponsor